TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01188655
Drug: Enbrel
Normalized name: Enbrel
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits.
Study: NCT04610359
Drug: MR-MC-01
Normalized name: MC-3
DrugBank: TMC-310911 (DB15623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal injection of 2.0 x 10,000,000/5ml (1mL \* 5 sites)
Study: NCT00683774
Drug: diazoxide
Normalized name: Diazoxide
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg orally three times per day for 10 days
Study: NCT01145404
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
Study: NCT02541565
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02541565
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02326987
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
Study: NCT00454350
Drug: Hectorol (doxercalciferol injection)
Normalized name: doxercalciferol Injection [Hectorol]
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00454350
Drug: Zemplar (Paricalcitol injection)
Normalized name: paricalcitol Injection [Zemplar]
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00315523
Drug: Levocetirizine
Normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00639808
Drug: 5% dextrose in water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml IV infusion over 30 minutes
Study: NCT00639808
Drug: TZP-101
Normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
Study: NCT02326987
Drug: Pregabalin 75mg
Normalized name: PREGABALIN 75MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
Study: NCT00600249
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
Study: NCT00600249
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/m2 every 21 days 6 cycles of 21 days
Study: NCT01402479
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ramipril 2.5mg twice a day
Study: NCT01550770
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peripheral IV of propofol at increasing dose levels
Study: NCT01437059
Drug: ALN-PCS02
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
Study: NCT02496377
Drug: Epoetin Alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01437059
Drug: Sterile Normal Saline (0.9% NaCl)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated volume to match active comparator
Study: NCT02587975
Drug: Evogliptin
Normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg
Study: NCT03922711
Drug: Pridopidine
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT04080349
Drug: Misoprostol 200Mcg Tab
Normalized name: MISOPROSTOL 200MCG TAB
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
Study: NCT00493649
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
Study: NCT00493649
Drug: Cytoxan
Normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
Study: NCT00493649
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
Study: NCT03167034
Drug: ACETAZOLAMIDE oral capsule
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
Study: NCT02639286
Drug: ISIS 304801
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of ISIS 304801 administered as SC
Study: NCT04616963
Drug: Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.
Study: NCT04616963
Drug: Emtricitabine Tenofovir Alafenamide 200/25 mg
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation
Study: NCT01838317
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00953667
Drug: Immediate Release Niacin, Extended Release Niacin, Endotoxin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
Study: NCT02726828
Drug: intrathecal morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
Study: NCT02726828
Drug: intrathecal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
Study: NCT02726828
Drug: intrathecal morphine + ketamine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
Study: NCT03038321
Drug: Tavanic
Normalized name: Cassia javanica whole extract
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
Study: NCT00730158
Drug: KD018
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
Study: NCT00730158
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
Study: NCT02290470
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy).
Study: NCT02290470
Drug: Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
Study: NCT00516321
Drug: eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25, 50, 75, 100 mg tablets taken once daily orally
Study: NCT00984009
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
Study: NCT00984009
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
Study: NCT02447965
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
Study: NCT00405080
Drug: GW679769 (Casopitant) oral tablets
Normalized name: maropitant Oral Tablet
DrugBank: Maropitant (DB11427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
Study: NCT00405080
Drug: Rifampin oral capsules
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
Study: NCT03360266
Drug: 5% Sodium Fluoride Varnish
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ffor children with ECC, this varnish effectively remineralizes the white spot lesion
Study: NCT02738008
Drug: ARC-520 Injection
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV injection
Study: NCT02738008
Drug: entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Study: NCT02738008
Drug: tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Study: NCT02738008
Drug: antihistamine
Normalized name: Antihistamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
Study: NCT01388517
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
Study: NCT01388517
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
Study: NCT02865681
Drug: Menopur
Normalized name: Menopur
DrugBank: Menotropins (DB00032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal versus injectable
Study: NCT02865681
Drug: Synarel
Normalized name: Synarel
DrugBank: Nafarelin (DB00666)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nasal
Study: NCT02865681
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02865681
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01388517
Drug: Petrolatum
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
Study: NCT00781378
Drug: rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA 100 mg continuous intravenous infusion for 2 hours
Study: NCT00781378
Drug: rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA 50 mg continuous intravenous infusion for 2 hours
Study: NCT01376089
Drug: Iodixanol
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol 320 mg I/mL as a single iv. administration.
Study: NCT01376089
Drug: Iopamidol
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
Study: NCT03262935
Drug: (vic-)trastuzumab duocarmazine
Normalized name: Trastuzumab duocarmazine
DrugBank: Trastuzumab duocarmazine (DB16342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous SYD985, Q3W
Study: NCT03428958
Drug: NUC-3373
Normalized name: NUC-7738
DrugBank: NUC-7738 (DB19148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC-3373
Study: NCT03428958
Drug: NUFOX
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NUC-3373 + oxaliplatin
Study: NCT03428958
Drug: NUFOX + EGFR inhibitor
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC-3373 + oxaliplatin + cetuximab/panitumumab
Study: NCT03428958
Drug: NUFIRI + EGFR inhibitor
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC-3373 + irinotecan + cetuximab/panitumumab
Study: NCT03428958
Drug: NUC-3373 + bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NUC-3373 + bevacizumab
Study: NCT00523146
Drug: Kanion Capsule
Normalized name: Arsenite anion
DrugBank: Arsenite ion (DB18509)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02639091
Drug: BAY 94-9343
Normalized name: Anti-mesothelin antibody-drug conjugate BAY 94-9343
DrugBank: Anetumab ravtansine (DB14809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).~In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)
Study: NCT02639091
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
Study: NCT02639091
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
Study: NCT01599104
Drug: Olmesartan
Normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg capsule one daily
Study: NCT00549640
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
Study: NCT01682408
Drug: Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
Study: NCT01682408
Drug: Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
DrugBank: Tamatinib (DB07159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
Study: NCT01682408
Drug: Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
Study: NCT00994097
Drug: NGR-hTNF
Normalized name: NGR-hTNF
DrugBank: Tengonermin (DB16689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
Study: NCT00994097
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
Study: NCT00994097
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
Study: NCT00994097
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
Study: NCT04479865
Drug: Aricept 5mg Tablet
Normalized name: Aricept 5mg Tablet
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet once daily
Study: NCT04479865
Drug: Aricept 10mg Tablet
Normalized name: Aricept 10mg Tablet
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet once daily
Study: NCT04479865
Drug: DA-5207 150mg
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 patch once weekly
Study: NCT01225211
Drug: Lumacaftor
Normalized name: Lumacaftor
DrugBank: Lumacaftor (DB09280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT01225211
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet.
Study: NCT01682408
Drug: Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
Study: NCT01682408
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg ranitidine
Study: NCT04479865
Drug: DA-5207 170mg
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 patch once weekly
Study: NCT00019747
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
Study: NCT01098344
Drug: Notch signaling pathway inhibitor MK0752
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01098344
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00803283
Drug: Hydromprphone Hydrochloride (HCl) OROS
Normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.